ERIS Lifesciences Ltd
NSE: ERIS BSE: 540596
₹1349.30
(-0.13%)
Thu, 12 Mar 2026, 05:07 am
Market Cap184B
PE Ratio42.61
Dividend0.54
Company History
2007
- The Company was incorporated as Eris Lifescience Private Limited.
- The name of the Company was changed to Eris Lifesciences Private Limited.
- The Company launched the Eris division focused on cardiology and diabetes segment.
2008
- The Company launched the Nikkos division focused on gastroenterology and orthopedics segment.
2009
- The Company launched the Adura division focused on cardiology and diabetes segment.
2011
- The Company launched the Montana division focused on gynecology and pediatrics segment.
2012
- The Company launched the Inspira division focused on cardiology segment.
2013
- The Company was awarded Competitive Strategy Leadership by Frost & Sullivan.
- The Company was awarded Emerging Companies Excellence for scalability of business model and managing operational efficiencies by Business Today and Yes Bank.
2014
- The Company launched the Victus division focused on anti-diabetes segment.
- The Company set up its Assam Facility.
2015
- The Company launched the Eris 2 division focused on pain management segment.
2016
- The Company acquired 40 registered and unregistered trademarks from Amay Pharmaceuticals Private Limited.
- The Company acquired 100.00% of the outstanding equity shares of Aprica Healthcare Private Limited.
- The Company acquired 75.48% of the outstanding equity shares of Kinedex Healthcare Private Limited.
2017
- The Company was converted to a public limited company and its name was changed to Eris Lifesciences Limited.
- The Company acquired the trademarks UNION, REUNION, and BON UNION.
- A fresh certificate of incorporation was issued by the Registrar of Companies, Gujarat, Dadra and Nagar Haveli on February 2, 2017.
2022
- Eris entered the dermatology therapy segment through the acquisition of Oaknet Healthcare for INR 6,500 million.
2023
- Eris acquired the Nephrology and Dermatology Branded Formulations business units of Biocon Biologics in India.
2024
- The Company acquired a 30% stake in Levim Lifetech Private Limited.
- The Company acquired a 100% stake in Eris Pharmaceuticals Private Limited.
Open Your Free Demat Account Now!
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800